Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Over 20% of All Generics under Restricted Shipments: FPMAJ
More than 20% of all generics on the Japanese NHI price list are under restricted shipments, according to a survey recently conducted by the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ). The survey was carried out between February 15…
To read the full story
Related Article
- Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
March 21, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
ORGANIZATION
- BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…